Skip to main content

Table 4 Soluble receptor and IL-1RA concentrations pre-cART and longitudinally over 12 weeks, categorized by neuropathic symptom status

From: Plasma cytokine profiles in HIV-1 infected patients developing neuropathic symptoms shortly after commencing antiretroviral therapy: a case-control study

Cytokine Time point Time effect Group effect
Median (IQR) (pg/mL) Neuropathic symptom-group Median (IQR) (pg/mL) Control group Median (IQR) (pg/mL)
sIL-1RI Baseline 29.6 (23.1; 41.0) 33.3 (23.2; 43.1) 25.5 (23.0; 34.3)
  Week 2 34.0 (26.6; 45.6) 36.9 (29.0; 48.3) 33.6 (25.2; 39.5)
  Week 4 37.6 (28.2; 45.6) 37.5 (27.4; 46.1) 38.7 (28.9; 42.9)
  Week 12 28.2 (23.4; 38.9) 34.5 (26.3; 44.2) 25.2 (22.5; 35.0)
sIL-1RII Baseline 4572 (1904.5; 6339.5) 4160.6 (1593.2; 5550.0) 4922.8 (2017.9; 6489.5)
  Week 2 4885.7 (2144.1; 7056.3) 4744.4 (2144.1; 6174.4) 4905.8 (2027.0; 8988.9)
  Week 4 5116.7 (2453.1; 7658.8) 5115.7 (2453.1; 7443.9) 5751.6 (2674.1; 8659.4)
  Week 12 5806.5 (2726.7; 8628.2) 5604.6 (2622.7; 8295.6) 6152.1 (2845.9; 8651.8)
sIL-2rα Baseline 1102.3 (728.1; 2021.5) 1068.2 (699.0; 2005.3) 1210.3 (757.1; 2383.1)
  Week 2 1049.2 (595.1; 1781.7) 1188.4 (638.5; 1831.3) 866.1 (472.3; 1589.2)
  Week 4 881.2 (580.8; 1763.4) 745.5 (595.0; 1230.0) 1032.1 (558.8; 1763.4)
  Week 12 733.3 (434.6; 1073.1) 647.1 (432.9; 869.5) 823.8 (610.9; 1264.5)
sIL-6R Baseline 9379.3 (6441.9; 12912.4) 9379.3 (6386.6; 12726.3) 9545.9 (6518.4; 15032.9)
  Week 2 9480.6 (7325.3; 14352.6) 10038.4 (7421.2; 14014.9) 9183.6 (6446.9; 15126.8)
  Week 4 11538.0 (8288.9; 14148.6) 11248.9 (7994.0; 12857.9) 11940.5 (9510.9; 14148.6)
  Week 12 8123.9 (6241.2; 12582.7) 8250.4 (6978.9; 12582.7) 7518.7 (5366.6; 11001.6)
sTNFRI Baseline 536.2 (288.7; 845.4) 551.4 (292.6; 860.6) 489.4 (284.7; 749.7)
  Week 2 560.9 (347.2; 799.5) 647.5 (417.4; 803.7) 516.4 (302.3; 782.2)
  Week 4 606.9 (379.0; 872.3) 646.0 (424.7; 742.0) 571.0 (379.0; 913.7)
  Week 12 455.1 (347.2; 750.5) 532.9 (416.5; 753.8) 415.2 (319.4; 612.3)
sTNFRII Baseline 5441.7 (4425.5; 7722.1) 5441.7 (4285.5; 8470.5) 5582.4 (4539.0; 7230.2)
  Week 2 5104.3 (3728.7; 6909.2) 5680.6 (4255.6; 7181.9) 4236.9 (3629.6; 6032.3)
  Week 4 4757.1 (3718.4; 6621.7) 4307.4 (3531.6; 6486.4) 5766.0 (4121.2; 6922.4)
  Week 12 4564.9 (3532.0; 6127.8) 4485.4 (3113.5; 6384.8) 4579.4 (3924.5; 5791.2)
IL-1RA Baseline 4.4 (0.0; 16.7) 10.2 (2.1; 18.8) 1.9 (0.0; 8.0)
  Week 2 3.4 (0.0; 16.7) 11.3 (0.8; 25.8) 0.4 (0.0; 14.0)
  Week 4 5.4 (0.0; 13.1) 5.7 (0.0; 11.5) 2.1 (0.0; 14.0)
  Week 12 3.4 (0.0; 14.0) 5.1 (0.8; 15.1) 0.0 (0.0; 10.2)
  1. Incident neuropathic symptoms developed within 12 weeks of starting cART.
  2. The control group refers to the symptom-free nested control group paired for previously identified risk factors.
  3. Time effect: Bold numbers denote values different from baseline, p < 0.05.
  4. Group effect: Bold numbers denote values different between groups compared to baseline, p < 0.05.
  5. Abbreviations: IQR interquartile range, sIL-1RI soluble IL-1 receptor I, sIL-1RII soluble IL-1 receptor II, sIL-2Rα soluble IL-2 receptor-α, sIL-4R soluble IL-4 receptor, sIL-6R soluble IL-6 receptor, sTNFRI soluble TNF receptor I, sTNFRII soluble TNF receptor II, IL-1RA IL-l receptor antagonist.